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Every week during the last year, people have been facing unimaginable circumstances surrounding the downturn in 
the economy. People have lost their jobs, lost eligibility for health coverage, exhausted savings and prematurely tapped 
into retirement savings. Imagine facing these issues along with a new diagnosis of cancer. It happens frequently 
and is a major challenge for patients and our comprehensive community cancer program.  
Medical costs for cancer treatment in the United States are high and continue to increase. The cost of medical care for 
a cancer diagnosis has nearly doubled since the mid 1980s. Treatment options have become more complex and costly 
but have resulted in more patients surviving this disease. With an aging population and improved screening, diagnosis 
and treatment options, the number of people with cancer has more than doubled; it now affects about 27.8 million 
people with the corresponding cancer expenditures reaching $979 billion. 
In calendar year 2009, St. Cloud Hospital entered 1,561 new cancer cases into its registry (representing cancers 
diagnosed and/or patients receiving treatment at St. Cloud Hospital, Coborn Cancer Center and CentraCare Radiation 
Oncology at Douglas County Hospital). Since 1994, more than 
18,800 patients have received their cancer care here. We recognize 
that these numbers reflect patient confidence in the diagnostic and 
treatment capabilities of our physicians and St. Cloud Hospital.
Having the available technology, drugs, physicians and staff, while 
critically important, is not all that is needed to support a patient 
and his/her family through diagnosis and treatment. During these 
tough economic times, addressing the financial challenges facing 
patients has become a key priority for our cancer program. We 
have worked hard to improve clinical services, assure available 
technology, add physician specialists and advance quality initiatives 
to enable optimal outcomes for our patients.  
We are equally proud of our efforts during the last year to provide 
more comprehensive survivorship support services to patients at 
no cost. While many cancer programs across the United States have been forced to cut back or omit support programs, 
we have been able to expand these services with support from St. Cloud Hospital and CentraCare Health Foundation. 
Program enhancements include:
• Oncology social workers who are available for inpatients at St. Cloud Hospital and outpatients at Coborn Cancer 
   Center. Coborn Cancer Center’s social worker has completed special certification to work with patients having 
   financial concerns, an ever-growing need for our patients.  
• Dedicated Coborn Cancer Center staff who assist patients to optimize available insurance benefits. These staff 
   members also act as liaisons with pharmaceutical-sponsored assistance programs to obtain low or no-cost drugs 
   based on patients’ financial situations. 
Cancer Report 2009 | 3
Achievements
Nicholas F. Reuter, MD, FACP
Cancer Medical Director
Jo Zwilling, RN, MBA
Cancer Program Director
• Additional disease site registered nurse care coordinators. There are now 
   three highly specialized coordinators available to work with patients, primary 
   care providers, oncologists and other specialists regarding breast, lung and 
   gastrointestinal (stomach, colorectal, esophagus, liver and pancreas) cancers. 
   The care coordinator may enter a patient’s life when a cancer is first suspected 
   or newly diagnosed. These specialized nurses are health care partners who help 
   with questions, education and support throughout the cancer journey.
• A transportation assistant, available to meet patients and families at the door 
   of Coborn Cancer Center and provide a wheelchair or an extra pair of hands 
   when needed.  
• Expert cancer-focused registered dietitians. These professionals provide 
   nutritional assessment and support to help patients and their families maintain 
   weight and nutrition. This improves the likelihood that they will complete 
   treatment and thus improve overall outcomes and quality of life.
• Access to a free educational program entitled “Tools for Making Health Care 
   Decisions.” This program uses evidence-based tools to teach community 
   members proactive decision support skills which can be helpful when faced 
   with a tough health care decision.  
• Emotional support for children through the CLIMB® (Children’s 
   Lives Include Moments of Bravery) program. Specially trained 
   facilitators provide ongoing sessions for children who have 
   a parent or primary caregiver with cancer.
• Support groups for many cancer diagnoses, art therapy and 
   other events sponsored by Coborn Cancer Center and several 
   other community care providers. All are well-received and free 
   to participants.
Even in the face of health care reform and the ever-changing 
landscape of oncology, we continue to strive to be a leader for 
quality, safety, service and value. We thank you for trusting us 
with your life and health. 
Coborn Cancer Center is proud 
to be a department of St. Cloud 
Hospital and is equally proud 
to provide the same high-quality 
care that St. Cloud Hospital is 
known for.
St. Cloud Hospital’s national
recognition includes:
•  Magnet Award for Excellence 
in Nursing (2004-2008, 
2009-2013) 
•  Thomson Reuters Top 100 
Hospital (1993, 1994, 1999,
2005-2009) 
•  An “America’s Best Hospital” 
U.S. News &World Report 
(2005-2009)  
Twilight at Coborn Cancer Center at the CentraCare Health Plaza.
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Life hits high note after cancer experience
* Intraperitoneal (IP) chemotherapy is a 
widely used treatment for ovarian cancer.
It delivers anti-cancer drugs directly into 
the abdomen through a tube in a more 
targeted approach than traditional 
chemotherapy. The treatment requires 
the expertise of a handful of various 
specialties. There are a relatively small 
number of ovarian cancer patients in 
our area, however, given the diverse 
medical specialties in the community 
and our commitment to offering 
cutting-edge treatments, we are able 
to offer IP chemotherapy to those who 
are candidates. 
Kirsten Hoese had a love for music 
during her teen and college years — 
but never had the time to pursue it. 
Life got busy with work, raising a 
family and then helping care for her 
grandson, Brock. So, ovarian cancer 
came as a startling diagnosis when 
she was 62. “It hit me hard — it 
just came out of the blue,” she said. 
“At first I was scared. I didn’t think 
I’d make it a year.”
Thankfully for Kirsten, Coborn 
Cancer Center offered intraperitoneal 
chemotherapy*, for which she was 
a perfect candidate. She credits her 
recovery to staying busy, reading, 
exercising, a healthy diet and caring 
for her grandson. “I wanted to be 
there for him,” she said.
After facing the music with cancer, 
today, Kirsten has struck a chord 
with her passion. She started taking 
voice lessons and enjoys her time 
with Brock. “I appreciate it all so 
much more . . . you have to make 
the most of every day!”
Kirsten Hoese, Elk River, 
ovarian cancer survivor
On the green, with a bigger smile
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Janna Cannon, Sauk Rapids, 
breast cancer survivor
After two of her sisters were diagnosed with breast cancer, Janna Cannon, age 57 of Sauk Rapids, decided not to 
put off her mammogram. Ten days later, she too, was diagnosed with breast cancer. All three sisters’ diagnoses came 
within 15 short months. 
“I wasn’t going to have reconstructive
surgery.” Janna said. But after 
exploring the possibility with her 
surgeon, John Houle, MD, Midsota 
Plastic Surgeons, she didn’t have 
a second thought about having 
a Deep Inferior Epigastric Artery 
Perforator (DIEP) flap procedure.*  
“It was a positive, life-changing 
experience,” Janna said. “It gave me 
hope — after being taken apart and 
put back together — of being not 
only the same me, but a better me.” 
Today, Janna spends her free time 
with family or on the golf course. 
After going through her cancer 
experience Janna says “It’s a 
better me, with a bigger smile!” 
* The “Deep Inferior Epigastric Artery 
Perforator” (DIEP) flap is a breast 
reconstruction procedure. DIEP flap is 
the latest and most technically advanced 
procedure for reconstructing a patient’s 
breast using her own tissue from the 
abdomen. DIEP flap may cause less pain, 
allow for a shorter hospitalization 
and decrease the chances of some 
complications.
6 | Cancer Report 2009
Hockey games and mammograms . . .
too important to miss
Shannon Petroske, St. Cloud, 
breast cancer survivor
Shannon Petroske, mother of three had it all, a loving family, an active life with her job and kids’ activities . . . and a 
family history of breast cancer. She always did self breast exams but followed her doctor’s advice to start mammograms 
at age 38. And thankfully so. The following year, Shannon was diagnosed with breast cancer. 
“I’m so glad I talked to my doctor when I did,” she said. “Had I waited until 40, I fear I would not be where I am today.” 
Between hockey, soccer and dance practice, Shannon makes sure never to miss important appointments.
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Journey with cancer can’t trump travels
Judy Scheuerell, Sartell, 
breast cancer survivor
* MammoSite® is a breast conservation 
therapy that delivers radiation in the 
space left when the tumor is surgically 
removed. MammoSite may be an option 
for patients with early-stage breast cancer, 
who are candidates for a lumpectomy 
and meet certain other criteria. A benefit 
of the therapy is the shortened radiation 
procedure time — five days total versus 
the traditional 35 days.
Judy Scheuerell has traveled to exotic locations such as India and Russia. But in 2007, her love of travel led to a foreign 
journey — a journey with breast cancer.
When Judy, 68, had her annual 
mammogram, they found a lump in 
her left breast. She had early-stage 
breast cancer. 
Judy was treated at the Coborn 
Cancer Center in St. Cloud and 
was fortunate enough to be a 
candidate for MammoSite® 5-Day 
Targeted Radiation Therapy.* 
“MammoSite therapy got me 
through my radiation treatment in 
less than a week and back to my 
normal, active life again,” Judy said. 
“The day that I went in for my 
mammogram to the end of 
MammoSite therapy took less than 
one month. And, I only had mild 
fatigue and discomfort. 
It was amazing.” 
Judy has returned to 
her everyday life and 
continues to do all 
the things she loves: 
play golf, tennis, 
bridge, ski, read and 
especially travel. 
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A focus on Women’s Cancers
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TABLE 1
Breast Cancer: AJCC Stage at Diagnosis
St. Cloud Hospital (SCH) and National Cancer Data Base (NCDB) 
©2010 National Cancer Data Base, Commission on Cancer 
Breast Cancer
Cancers that occur primarily in women include breast, uterine 
and ovarian. In the United States, these three cancers accounted 
for 36% of the new cancers diagnosed in women during 2009. 
There were 785 women newly diagnosed with cancer during 
2009 at St. Cloud Hospital. Breast, uterine and ovarian cancers 
accounted for 45% of these cases.
For this annual report, Maria Mallory, MD, and Christian Schmidt, 
MD, surgeons with CentraCare Clinic – River Campus, were asked 
to take a close look at breast cancer care at St. Cloud Hospital. 
Robert Stocker, MD, gynecologist with CentraCare Clinic —
Women & Children and Nathaniel Reuter, MD, surgical oncologist
with CentraCare Clinic – River Campus, took a further look into 
ovarian and endometrial cancers. The following focus studies are a 
summary of their findings and the impact on St. Cloud Hospital and
the community.
Maria Mallory, MD Christian Schmidt, MD
Incidence
In 2009, there were 306 female breast cancer 
cases diagnosed and/or treated at St. Cloud 
Hospital. This compares to 258 women in 
2008. Although the national incidence of 
breast cancer has decreased about 2% per 
year from 1999-2006, the numbers diagnosed 
and/or treated by St. Cloud Hospital continue 
to increase. This is likely due to increasing 
population growth in the service area and 
availability of comprehensive breast services 
located at St. Cloud Hospital rather than 
increased incidence.   
Screening
According to the Centers for Disease Control (CDC), 81% of women, 
ages 50-74, received the recommended mammography screening for 
breast cancer in 2008. Combining data from 2002-2006, the percent 
of women, ages 40 and older, who reported having a mammogram in 
the previous two years was somewhat lower, in rural areas (78%) than 
urban areas (82%) in Minnesota. New controversial breast cancer screening recommendations from the United States 
Preventative Services Task Force (USPSTF) were published in 2009. Women, ages 40-49, were recommended to 
not have an annual mammogram and women, ages 50-75, were only to be screened every two years instead 
of annually. These new recommendations resulted 
in confusion and controversy. At this time, most 
health care providers continue to follow the 
more conservative recommendations by the 
American Cancer Society — to begin mammography 
screening at age 40 and to continue annually 
regardless of age unless the woman has 
serious chronic health problems and a limited 
life expectancy. 
Stage at diagnosis
The majority of breast cancer cases diagnosed at 
St. Cloud Hospital are considered early stage (0-1) 
using the American Joint Committee on Cancer 
(AJCC) staging system. As seen in Table 1, these cases 
accounted for 57% of the total breast cancer cases seen at St. Cloud 
Hospital. The hospital’s breakdown by stage is comparable to 
Minnesota and national rates as reported by the National Cancer 
Data Base (NCDB). Today, most women are diagnosed by ultrasound 
or stereotactic needle biopsy as an outpatient procedure in contrast 
to open surgical biopsy done in the past. Early diagnosis for women 
diagnosed with breast cancer at St. Cloud Hospital is attributed to 
focused emphasis on screening by providers and women themselves.  
Treatment
A diagnosis of early stage breast cancer offers a variety of treatment 
options beginning with surgery — mastectomy versus breast conserving 
surgery. Research shows women with early stage breast cancer 
treated with breast conserving surgery plus radiation therapy were 
as likely to be alive and disease-free 20 years later as women treated 
with mastectomy. Fifty-six percent of women with stage I-II breast cancer treated surgically at St. Cloud Hospital had 
breast conserving surgery. This compares well with Minnesota and national statistics (Table 2).
An important national measure of quality is radiation therapy administered within one year of diagnosis for women under 
age 70 who received breast conserving surgery. Even when considering two patients who declined the recommended radiation, 
St. Cloud Hospital had 99% of patients receiving the recommended radiation therapy.  
Women are referred for cancer risk assessment and genetic counseling when their 
personal or family history is suggestive of familial or hereditary cancer. This is 
another important step in the follow-up treatment for women with breast cancer. 
Survival
With a 91% overall five-year survival rate for breast cancer, St. Cloud Hospital 
compares favorably to Minnesota and national rates (Table 3). When considering 
long-term survival rates, the rates reflect women treated using past therapies and 
may not reflect more recent advances in early detection or treatment. 
Summary
Breast care continues 
to evolve. Awareness 
and screening programs 
have lead to earlier 
diagnosis. A multi-
disciplinary approach
has become the 
standard of care. A new 
weekly breast cancer 
conference has been 
developed to review new breast cancers and treatment 
options. This is one example of our commitment to 
state-of-the-art care.
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TABLE 2
Breast Conserving Surgery vs Mastectomy
AJCC Stage I and II Cases
St. Cloud Hospital* (SCH) and National Cancer Data Base (NCDB) 
   *  SCH Cases: Only patients receiving surgery at St. Cloud Hospital
      ©2010 National Cancer Data Base, Commission on Cancer 
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TABLE 3
Breast Cancer: Five Year Observed Survival Rates
All Stages: 1998 to 2002
St. Cloud Hospital (SCH) and National Cancer Data Base (NCDB) 
©2010 National Cancer Data Base, Commission on Cancer 
The Breast Center extends its services
and expert care to women across 
Central Minnesota with its Mobile 
Mammography Program. A fully 
equipped vehicle visits more than 
a dozen communities.
In 2009, the mobile program screened 
2,458 women, including 114 done at 
reduced or no cost through SAGE, 
Minnesota’s cancer screening program.
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Uterine  (Endometrial) 
Cancer
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TABLE 4
Endometrial Cancer: Age at Diagnosis
St. Cloud Hospital (SCH) and National Cancer Data Base (NCDB) 
©2010 National Cancer Data Base, Commission on Cancer 
Robert Stocker, MD 
Incidence
Endometrial cancer starts in the lining of the uterus. It is the most common type of uterine 
cancer and accounts for approximately 6% of the new cancers diagnosed in women each 
year in the United States. The American Cancer Society estimates that more than 43,000 
cases will be diagnosed in 2010 across the country. There were 31 patients diagnosed 
and/or treated for endometrial cancer at St. Cloud Hospital during 2009. This represented 
4% of the newly diagnosed cancers in women seen at the hospital during that year. 
Screening
Although the cause of endometrial cancer is unknown, increased estrogen levels appear to play a role. There is 
no standard or routine screening test for endometrial cancer, however, all women should have a pap/pelvic exam 
routinely. If a woman is determined to be at high risk by her physician, screening annually with endometrial biopsy 
and/or transvaginal ultrasound, 
beginning at age 35, may be 
recommended. If a woman after 
age 40 experiences a change in 
bleeding pattern, or there is 
vaginal bleeding in a menopausal 
woman, there should be an office-
based endometrial biopsy with a 
transvaginal ultrasound. More than 
half of women diagnosed with 
endometrial cancer are between 
the ages of 50-69 as seen in 
Table 4, which compares the age 
of diagnosis of St. Cloud Hospital 
cases with Minnesota and 
national cases. Abnormal vaginal 
bleeding is the most common 
symptom, presenting in nine out 
of ten women diagnosed. This would include vaginal bleeding or spotting in post-menopausal women and bleeding 
between periods in pre-menopausal women. Other symptoms may include pelvic or lower abdominal pain. This 
supports women continuing to have regular pelvic exams and pap smears as recommended by their providers.
Stage at diagnosis
Many endometrial cancers are diagnosed at an 
early stage (AJCC 0-I). Of the women diagnosed 
and/or treated at St. Cloud Hospital during 2007-09, 
50% were diagnosed as stage I. This is consistent 
with Minnesota and national findings (Table 5).
Treatment
Treatment decisions are based on the stage of the 
tumor. The majority of women with early stage 
endometrial cancer (meaning the cancer has not yet 
spread outside of the uterus) will be cured simply 
by the surgical removal of the uterus. For cases with 
more extensive tumors, radiation or radiation and 
chemotherapy, in addition to more extensive surgery, are considerations; many require a lymphadenectomy 
(removal of surrounding lymph nodes). Recent years have brought changes and eased the way radiation is used to 
treat endometrial cancer. In addition, in 2009 St. Cloud Hospital added a surgical oncologist with the ability to treat 
more advanced uterine and ovarian cancers. 
Survival
Since the majority of cases diagnosed and treated 
at St. Cloud Hospital are stage I, it is important to look 
at the survival rate for this patient group. Observed 
five-year survival for stage I patients diagnosed and
treated at St. Cloud Hospital is 96%. This compares 
favorably to Minnesota data (91%) and national data 
(90%) (Table 6).
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TABLE 5
Endometrial Cancer: AJCC Stage at Diagnosis
St. Cloud Hospital (SCH) and National Cancer Data Base (NCDB)* 
©2010 National Cancer Data Base, Commission on Cancer 
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TABLE 6
Endometrial Cancer: Five Year Observed Survival Rates
Stage 1: 1998 to 2002
St. Cloud Hospital (SCH) and National Cancer Data Base (NCDB) 
©2010 National Cancer Data Base, Commission on Cancer 
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Nathaniel Reuter, MD, 
joined the surgical team 
at St. Cloud Hospital 
in 2009. Dr. Reuter has 
received specialized 
training for staging 
and optimal surgical 
management of cancer patients, especially
helpful when treating endometrial and 
ovarian cancers.
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Ovarian Cancer
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TABLE 7
Ovarian Cancer: Age at Diagnosis
St. Cloud Hospital (SCH) and National Cancer Data Base (NCDB): 2000 to 2007 
©2010 National Cancer Data Base, Commission on Cancer 
Incidence
Ovarian cancer is the ninth most common cancer in women. The American Cancer Society estimates 21,880 new 
cases of ovarian cancer will be diagnosed in the United States during 2010. There were 16 women diagnosed and/or 
treated for ovarian cancer at St. Cloud Hospital during 2009. This represented 2% of the newly diagnosed cancers 
in women seen at St. Cloud Hospital that year. Although ovarian is a relatively rare cancer, receiving a diagnosis of 
ovarian cancer is difficult and life-changing. 
A significant risk factor for ovarian cancer is age — most ovarian cancers develop after menopause. This is supported 
by St. Cloud Hospital, Minnesota and national data shown in Table 7. In the years 2000 to 2007, more than 50% 
of ovarian cases were diagnosed at age 60 or older, and greater than 75% were diagnosed at age 50 and older. 
Another important risk factor is a strong family history of breast or ovarian cancer. According to the American Cancer 
Society, up to 10% of ovarian cancers result from an inherited tendency to develop the disease. Thus, a genetic consult 
may be advised for women with an increased familial risk.  
Screening
There is currently no effective routine screening for early detection of ovarian cancer. Women who are at high risk
of developing ovarian cancer or have symptoms may be screened/diagnosed with a pelvic exam, transvaginal 
ultrasound, a blood test for a tumor marker referred to as CA125 and/or a CT scan. Although these tests are useful in 
diagnosing ovarian cancer, they are not currently used for routine screening in asymptomatic or low risk women. 
Physicians frequently rely on report of symptoms such as bloating/pelvic pain/change in bleeding pattern and pressure. 
Currently, there are research studies looking at the effect of routine screening on mortality. Hopefully in the future 
there will be a way to detect ovarian cancer before a woman is symptomatic. 
Stage at diagnosis
Staging of ovarian cancer must be accurate at the time of diagnosis to determine the most effective treatment 
and overall prognosis. The primary goal of surgery, usually the first treatment for ovarian cancer, is to obtain tissue 
samples for diagnosis and 
staging and to remove as much 
cancer tissue as possible. 
Unfortunately, the majority 
of cases are diagnosed in later 
stages, AJCC stage III, followed 
by stage IV. Table 8 compares 
St. Cloud Hospital’s stage at 
diagnosis to similar cancer 
programs in Minnesota and 
nationally. St. Cloud Hospital’s 
breakdown by stage is similar 
to Minnesota data, except for 
stage IV. St. Cloud’s lower percentage may be explained 
by the fact that patients with clinically obvious advanced 
disease at diagnosis are frequently referred to academic 
medical centers. The number of academic referrals is 
expected to decrease with the 2009 recruitment of a 
surgical oncologist. 
Over the past few years, ovarian cancer has been referred 
to as the “silent killer” because it usually wasn’t discovered 
until it had spread and was in a late stage. New evidence 
shows that women with early stage disease may indeed 
have symptoms, although subtle. Current efforts are being 
made to educate women and providers on the early signs 
and symptoms of ovarian cancer to increase detection at 
an early stage.
Treatment
Treatment involves surgery and usually chemotherapy. The intent of surgery is to remove as much of the tumor as 
possible and is referred to as debulking. Optimal surgical debulking is very important to increase survival. After 
recovery from surgery, women diagnosed with ovarian cancer may be referred for chemotherapy. Since 2006, women 
with AJCC stage III ovarian cancer may be offered intraperitoneal (IP) chemotherapy along with standard intravenous 
chemotherapy. IP chemotherapy infuses anti-cancer drugs directly into the peritoneal cavity (the space that contains the 
abdominal organs) through a thin tube. IP chemotherapy requires advanced skill and experience for the surgery and 
the chemotherapy administration. IP chemotherapy allows higher doses and more frequent administration of the drugs 
and appears to be most effective in killing cancer cells where the ovarian cancer is likely to spread or recur first. Even 
though IP chemotherapy has been available at St. Cloud Hospital since 2006, not every woman is a candidate. It is 
important to realize that treatment for ovarian cancer requires a multi-disciplinary approach, starting with surgery, 
intraperitoneal therapy, when indicated, systemic chemotherapy and sometimes radiation. Even with new research 
findings changing the treatment of ovarian cancer, additional studies are needed to further advance screening, early 
detection and treatment of this complicated disease. Participation in a clinical trial is always considered when a 
patient is diagnosed with ovarian cancer.
Survival
Ovarian cancer causes more deaths than any other cancer of the female reproductive system with an estimated 
13,850 deaths projected for 2010 by the American Cancer Society. The high mortality associated with ovarian cancer 
is evident when looking at the overall five-year survival rate for all ovarian cases diagnosed from 1998-2002, in 
Minnesota (48%) and national (41%), as reported through the National Cancer Data Base. It also is important to note 
that the overall five-year survival rate during the same timeframe for AJCC Stage I, in Minnesota (90%) and nationally 
(88%), proves that early detection is key to the survival of women with ovarian cancer. 
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TABLE 8
Ovarian Cancer: AJCC Stage at Diagnosis
St. Cloud Hospital (SCH) and National Cancer Data Base (NCDB)* 
   *  NCDB data from programs designated as Community Hospital Comprehensive Cancer Programs
    by the Commission on Cancer
      ©2010 National Cancer Data Base, Commission on Cancer 
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Activity Report
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TABLE 9
AJCC* Stage Group at Diagnosis: 2009 Analytic Cases
(Total Cases and Top Seven Sites) 
AJCC Stage **
SITE                                 0               I               II              III            IV     UNKNOWN     N/A***     TOTAL
ALL CASES                      168           352            396            191          256             28                 170          1561
Breast                           70           113           73             32           16              2                  0            306
Prostate                         0              0             203            19           13              1                  0            236
Lung/Bronchus              0             37            17             44          103             2                  4            207
Colorectal                     51            39            23             28           15              2                  4            162
Malignant Lymphoma    0             28            18             10           33              1                  0             90
Bladder                         41            10             5               3             5               0                  0             64
Kidney                           1             29             6               8            11              1                  0             56
   *  (AJCC) = American Joint Commission on Cancer
  **  Collaborative Stage Derived
***  N/A: (Not Applicable): Cancers that do not have an AJCC staging scheme
TABLE 10
Submitted by cancer registry
The St. Cloud Hospital cancer registry 
remains busy collecting and reporting 
important information about cancer 
cases that are diagnosed and/or initially 
treated (analytic cases) at St. Cloud 
Hospital, Coborn Cancer Center and 
Radiation Oncology at Douglas County 
Hospital in Alexandria. The information 
collected by the cancer registrars 
goes beyond the initial cancer 
diagnosis and includes a complete 
abstract of the patient’s disease from 
diagnosis to end of life. Data collected 
by the registry is submitted to the 
Minnesota Cancer Surveillance System 
and the Commission on Cancer’s (CoC’s)
National Cancer Data Base (NCDB).
The registry collected information 
on 1,561 new cases during 2009 
(Table 12). These cases, added to the 
17,275 cases already in the registry database, total 18,836 cases that are now followed by the cancer registry. 
The current follow-up rate for all living cancer patients entered into the registry data base since 1994 is 95% which 
exceeds the CoC’s requirement of 80%. Following patients throughout their life span is vital to understanding the 
outcomes of treatment and provides accurate survival information.
The trend in the number of analytic cancer cases has steadily increased (Table 9) over the past 13 years. The most 
frequently occurring cancers 
continue to be breast, 
prostate, lung, colon/rectum, 
malignant lymphoma, 
with bladder and kidney 
following closely (Table 10). 
Together, these cancers 
made up 72% of all 
St. Cloud Hospital cases 
in 2009. The ratio of cases 
at this facility compares 
well with the estimated 
cases for Minnesota and the 
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Site Incidence Data at St. Cloud Hospital
ALL SITES                                       2007                 2008                 2009
Head and Neck                               57                     33                     35
Lip and Oral Cavity                    19                   11                    6
Pharynx                                      18                   11                   13
Nasal Cavity/Paranasal Sinuses    1                     1                     1
Salivary Glands                           10                    2                     4
Larynx                                         9                     8                    10
Other Head and Neck                 0                     0                     1
Digestive System                           276                   266                   253
Esophagus                                  20                   11                   20
Stomach                                     22                   22                   13
Colon                                        126                 139                 111
Rectum, Rectosigmoid                50                   45                   51
Anus/Anal Canal                          7                     2                     4
Liver & Bile Ducts                        7                     6                     7
Pancreas                                     34                   24                   30
Other Digestive                          10                   17                   17
Respiratory System                        232                   185                   210
Lung/Bronchus                          227                 183                 207
Other Respiratory                        5                     2                     3
Hematopoietic/Lymphoid            146                   159                   157
Leukemia                                    36                   33                   29
Multiple myeloma                      15                   18                   27
Other Hematopoietic                  25                   29                   11
Hodgkin Lymphoma                    9                    12                   15
Non-Hodgkin Lymphoma           61                   67                   75
Bone                                                  4                       2                       0
Connective Tissue                           4                       4                       9
Skin                                                  45                     34                     32
Melanoma                                  44                   32                   31
Other skin                                   1                     2                     1
Breast                                              272                   259                   306
Female Genital                                42                     51                     55
Cervix Uteri                                 6                     4                     7
Corpus Uteri                               20                   30                   31
Ovary                                         16                   14                   16
Vulva                                           0                     1                     1
Other                                           0                     2                     0
Male Genital                                   302                   248                   254
Prostate                                     291                 237                 236
Testis                                            9                    11                   13
Other Male Genital                     2                     0                     5
Urinary                                            137                   140                   126
Bladder                                        66                   70                   64
Kidney/Renal pelvis                     68                   66                   56
Other Urinary                               3                     4                     6
Brain and CNS                                 36                     48                     54
Brain (Benign)                               1                     1                     2
Brain (Malignant)                         19                   25                   32
Other Brain and CNS                   16                   22                   20
Endocrine                                        41                     50                     46
Thyroid                                        35                   40                   40
Other                                            6                    10                    6
Unknown Primary                           20                     24                     19
Other/Ill-defined Sites                    4                       7                       5
TOTAL                                            1618                 1510                1561
TABLE 12
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TABLE 11
2009 Incidence of Top Cancer Sites
(Compared to Total Number of Cancer Sites) 
St. Cloud Hospital vs Minnesota and Nationwide 
   *  Minnesota and nationwide statistics taken from the American Cancer Society (ACS) Facts/Figures 2009
  **  Breast and colorectal numbers include invasive cancers only. The ACS statistics do not provide estimates
      for non-invasive breast or colon/rectal cancer.
United States as published in the American Cancer Society’s 
“Cancer Facts and Figures 2009.” (Table 11).   
For optimal quality outcomes, lower stage at diagnosis is 
desired and results in the availability of more treatment options 
and improved survival ratios. Some cancers are easier to screen 
for and result in higher percent diagnosis at an earlier stage. 
However, due to lack of effective screening methods, early 
stage diagnosis is not always possible. This is the case with 
lung cancer. The breakdown of stage at diagnosis for the top 
seven most frequently diagnosed cancers at St. Cloud Hospital 
generally compares to state and national data (Table 10). 
An integral role of St. Cloud Hospital cancer registry is to 
provide information to monitor quality outcome measures such 
as volume, survival, and use of and adherence to clinical 
practice guidelines. In addition, the registry provides data 
for breast and colorectal cancer quality measures developed
by the CoC. The registry’s data also meets quality standards
(accuracy and timeliness) set by the CoC and the NCDB. 
During 2009, the cancer registry achieved an abstracting
timeliness of three and a half months — which well exceeds
the CoC’s requirement of six months — to meet standards 
for an accredited cancer program. More than 1,400 cancer
programs submit data to the NCDB, which reflects the 
diagnosis and treatment of more than 70% of the newly 
diagnosed cancer cases in the United States.
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a quality cancer program
Components of 
Measuring the quality of cancer care is much more complicated than it seems at first glance. At Coborn Cancer Center, 
we have made diligent efforts to monitor indicators and outcomes, and compare our results to national data. We 
compare things like stage at diagnosis, turnaround times, quality of life, best practices, survival rates, etc. These 
findings can be viewed by going to www.centracare.com.
Recently there have been news articles and reports about misdiagnoses and erroneous treatment for cancer. How does 
a patient find the best and most appropriate place to receive their cancer care? 
Things to consider when looking for a quality cancer program:
Comprehensive, state-of-the-art care
Changes in the way cancer is diagnosed, treated and managed 
are happening every day. Initiatives in cancer care include 
interdisciplinary care (all the specialists collaborating to provide 
the best plan); coordinated care, survivorship (follow up and 
support during and after treatment); and integration of new 
and innovative treatments and procedures. All this requires 
a tremendous financial investment and philosophy of 
commitment by the organization. Awareness of services to 
support state-of-the-art care is a factor to consider in selecting 
a cancer care provider.  
Volume
Patient volume is another important measure of quality health care. Current literature suggests a high number of cancer 
patient visits indicate physicians may be more familiar with, and more practiced at, treating certain types of cancer. 
More than 1,550 patients are newly diagnosed or treated at St. Cloud Hospital each year. Most of these patients 
receive all of their treatment and follow-up at Coborn Cancer Center. Annually, there are more than 18,000 patient 
appointments with providers and greater than 43,000 appointments for services at Coborn Cancer Center. 
Research
Research is an important component of comprehensive care. Access to cancer research studies can provide patients 
with cutting-edge care options. In addition, participation in research advances cancer care by identifying effective 
cancer treatments. More than 50 studies are open for patient enrollment 
at any given time at Coborn Cancer Center. Patients are screened for clinical 
trial eligibility throughout their cancer care journey. Currently, more than 
320 patients are actively being followed while on a cancer research study 
at Coborn Cancer Center.   
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Location
Most patients prefer to have their care close to home. Diagnosis, treatment 
and ongoing follow up for cancer requires frequent visits with the specialist 
and long hours receiving tests and treatment at the cancer center. Cancer care 
is not provided in isolation by a single provider but is a partnership between 
the primary care physician and the cancer specialist (medical and/or radiation 
oncologist) and typically supported behind the scenes by numerous specialists 
such as surgeons, pathologists, radiologists, geneticists, advanced practice 
providers and others with expertise in cancer care. There are more than 
400 specialists at St. Cloud Hospital who work together to support patients 
and their primary care providers during their cancer journey.  
Accreditation, recognition & certification
Coborn Cancer Center has been accredited by the American College of Surgeon’s 
Commission on Cancer (CoC) for more than 20 years. The CoC awards accreditation 
to programs that provide the best in diagnosis and treatment of cancer. In addition, the Coborn Cancer Center 
Radiation department has obtained accreditation status by the American College of Radiology. This accreditation 
recognizes quality radiation oncology practices through impartial, 
third-party peer review.  
Although national certification is not a requirement of employment, 
our nurses are committed to providing quality care. This is reflected 
through the number of nurses currently holding national certification. 
Currently, 63% of the nurses at Coborn Cancer Center hold national 
oncology certification.
Thomson Reuters®, a leading health care data company, recognized 
St. Cloud Hospital as a Top 100 Hospital for 2009. St. Cloud Hospital 
was one of 100 hospitals selected from a final pool of more than 
3,000 hospitals nationwide.
Thomson Reuters also honored St. Cloud Hospital with its “Everest
Award for National Benchmarks.” The 23 Everest Award winners have 
reached the highest level of accomplishment on the 100 Top Hospitals 
national balanced scorecard — balanced performance combined with the fastest rates of long-term improvement. 
St. Cloud Hospital is one of only two Minnesota 
hospitals to win the Everest Award.
Having obtained Outstanding Achievement as a CoC 
certified program, we continually strive for excellence 
in cancer care. Should you or your family need cancer 
services, we are confident in our ability to provide 
the quality and resources you would expect to receive 
from the best comprehensive cancer program.
For more information on outcome measures and to look at our 
quality reporting for select cancer sites, please visit our Web site at 
www.centracare.com/specialty_centers/cancer/quality_measures.html.
When a community comes together
Casting for a Cure
For Tracy and Joe Schulte, the fight against cancer became a personal affair. Tracy’s mother, Sandy Karasch, lost her 
battle to Multiple Myeloma in November 2008. Through their experience, they gained a greater understanding of the 
impact cancer has on the patient and their family. Inspired by Sandy’s journey, and the knowledge that three of every 
four American families will have at least one family member diagnosed with cancer, the Karasch family created the 
Greater Minnesota Fight for a Cure organization.
Along with a group of dedicated volunteers, they 
organized the inaugural “Casting for a Cure,” event — 
a fundraiser to raise funds 
for cancer awareness, 
prevention and resources. 
With the help of a very 
supportive Central 
Minnesota community, 
they raised more than 
$25,000 for the CentraCare Health Foundation. 
Bringing families and community together, they are 
making a difference.
Kidney Klimb 2010
Watching your father lose his battle with kidney cancer is no easy feat. 
For Jesse Godzala, that experience became the catalyst to make a difference 
in the lives of other families. Reflecting on how the experience impacted 
his family, and realizing that other families may be experiencing the same 
challenges, Jesse set out to do something unique and different — climb 
Mount Kilimanjaro to raise awareness and money for kidney cancer. 
With the support of individuals and organizations in Central Minnesota, 
Jesse, sister Matti, and three others 
raised more than $8,500 in 
Kidney Klimb’s first year to assist 
low-income families with the costs 
of medical care. By partnering 
with CentraCare Health Foundation 
and Coborn Cancer Center, 
Kidney Klimb has harnessed the 
power of community to support patients and families battling kidney cancer. 
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Multiple myeloma cancer facts:
• More than 20,000 new cases 
   are diagnosed each year;
• Average age at diagnosis is 70; 
   and
• Men have a 58 percent higher 
   incidence rate than women.
   — Leukemia Lymphoma Society
Kidney cancer facts:
• More than 58,000 new cases 
   are diagnosed each year;
• Lifetime risk of getting kidney 
   cancer is about 1 in 70; and
• Men are more likely to be diagnosed 
   with kidney cancer than women.
   — American Cancer Society
Sandy and husband, Rick Karasch, 
with their eight grandchildren 
(Spring 2007).
The first Kidney Klimb took place on Mount
Kilimanjaro, Tanzania, Africa.
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a difference
Almeda Ella Pollish Fund
Aunt Leona Fund
Breast Cancer 
Greatest Needs Fund
Cancer Survivorship 
Network Fund
Carl & Marilyn Savage Fund
Coborn Cancer Center 
Endowment Fund
Coborn Cancer Center
Greatest Needs Fund
Craig & Lynn Dahl Fund
Dr. Harold E. Windschitl  
Cancer Research Fund 
Cancer Named Funds
Fund-naming opportunities are available for Coborn Cancer Center.
The staff, physicians and patients extend our utmost gratitude.
For more information on supporting these funds, or establishing
your own fund, please call CentraCare Health Foundation at
(320) 240-2810. For a complete list of individual benefactors,
please visit www.centracare.com/foundation/benefactors.html.
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Quinlivan & Hughes Fund
Surviving with Style Fund
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Coborn Cancer Center
Cancer is not in a recession — it touches all of us, every day. Last year, 
more than 968 individuals gave in excess of $336,875 to support the 
cancer funds of the CentraCare Health Foundation and made a difference 
in the lives of those who find themselves facing cancer. 
Whether it’s helping fund early detection 
initiatives, patient education, survivorship 
services or care coordinator activities, your 
individual gift makes an enormous difference.
Though times are tough, we remain focused 
on our vision to become the leader in 
Minnesota for quality, safety, service and
value. Your generous support ensures quality
and patient-centered care at every turn. 
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Special recognition
Congratulations to Juli Sanner, RN, OCN, CBCN, 
breast care coordinator, who recently achieved 
national certification and celebrated 11 years of 
outstanding service. Juli holds dual national 
certifications in oncology nursing and as a 
breast care certified nurse.
Juli is a familiar face representing compassionate, 
quality breast cancer care for our community. 
Juli assures patients receive timely, coordinated 
care based on nationally accepted standards. 
In addition, she facilitates support groups, 
educates the community and helps raise funds 
to improve patient care. We are honored to have 
her as a part of our cancer care team.
Juli Sanner, RN, OCN, CBCN, breast care
coordinator.
